MedTrace Logo

Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome

NCT03520153 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2019-09-04

No results posted yet for this study

Summary

The investigators' objective is to understand the pathogenesis of diabetes mellitus in Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) by: 1) establishing the contributions of insulin resistance versus impaired insulin secretion, 2) investigating presence of excess glucagon signaling by measuring gluconeogenesis and glycogenolysis, and 3) investigating a potential interaction between diabetes and intraductal papillary mucinous neoplasms (IPMNs).

Conditions

  • McCune-Albright Syndrome
  • Fibrous Dysplasia
  • Intraductal Papillary Mucinous Neoplasm
  • Diabetes Mellitus

Interventions

PROCEDURE

Hyperinsulinemic Euglycemic Clamp and 2H20

Test is used to assess insulin effects on hepatic glucose production.

PROCEDURE

Hyperglycemic Clamp

Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.

DIAGNOSTIC_TEST

Oral Glucose Tolerance Test

The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Cemre Robinson, MD · Yale University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-07
Primary Completion
2021-08-31
Completion
2021-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03520153 on ClinicalTrials.gov